WO2017221214A1 - Crystalline forms of salts of lenvatinib - Google Patents

Crystalline forms of salts of lenvatinib Download PDF

Info

Publication number
WO2017221214A1
WO2017221214A1 PCT/IB2017/053776 IB2017053776W WO2017221214A1 WO 2017221214 A1 WO2017221214 A1 WO 2017221214A1 IB 2017053776 W IB2017053776 W IB 2017053776W WO 2017221214 A1 WO2017221214 A1 WO 2017221214A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
lenvatinib
hydrobromide
tosylate
hydrochloride
Prior art date
Application number
PCT/IB2017/053776
Other languages
French (fr)
Inventor
Narikolla Venkata Subba REDDY
Ashwini Kumar Kapoor
Asok Nath
Mohan Prasad
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2017221214A1 publication Critical patent/WO2017221214A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention provides a crystalline form of lenvatinib hydrochloride, a crystalline form of lenvatinib hydrobromide, a crystalline form of lenvatinib tosylate, processes for their preparation, and pharmaceutical compositions thereof.
  • the present invention further relates to the use of these crystalline forms of salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
  • Lenvatinib mesylate of Formula I is chemically known as 4-[3-chloro-4-(N'- cyclopropylureido)phenoxy] -7-methoxyquinoline-6-carboxamide methanesulfonate .
  • Lenvatinib mesylate is a kinase inhibitor indicated for the treatment of differentiated thyroid cancer (DTC) as single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine -refractory DTC and for the treatment of renal cell cancer (RCC) in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
  • DTC differentiated thyroid cancer
  • RCC renal cell cancer
  • U.S. Patent No. 7,253,286 provides a process for the preparation of lenvatinib.
  • U.S. Patent No. 7,612,208 provides processes for the preparation of crystalline lenvatinib hydrochloride, crystalline lenvatinib hydrobromide, and crystalline lenvatinib tosylate.
  • the present invention provides a crystalline form of lenvatinib hydrochloride, a crystalline form of lenvatinib hydrobromide, a crystalline form of lenvatinib tosylate, processes for their preparation, and pharmaceutical compositions thereof.
  • the present invention further relates to the use of these crystalline forms of salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
  • Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
  • XRPD X-Ray Powder Diffraction
  • FIG. 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
  • DSC Differential Scanning Calorimetry
  • Figure 3 depicts a Fourier-Transform Infrared (FTIR) spectrum of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
  • FTIR Fourier-Transform Infrared
  • Figure 4 depicts an XRPD pattern of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
  • Figure 5 depicts a DSC thermogram of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
  • Figure 6 depicts a FTIR spectrum of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
  • Figure 7 depicts an XRPD pattern of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
  • Figure 8 depicts a DSC thermogram of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
  • Figure 9 depicts a FTIR spectrum of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
  • solvent includes single solvents or solvent mixtures, such as water, esters, alkanols, halogenated hydrocarbons, ketones, ethers, polar aprotic solvents, or mixtures thereof.
  • esters include ethyl acetate, n-propyl acetate, isopropyl acetate, and n- butyl acetate.
  • alkanols include those primary, secondary, and tertiary alcohols having from one to six carbon atoms.
  • alkanols include methanol, ethanol, n- propanol, isopropanol, butanol, 2-methoxyethanol, and 2-ethoxyethanol.
  • halogenated hydrocarbons include dichloromethane, chloroform, and 1,2-dichloroethane.
  • ketones include acetone and methyl ethyl ketone.
  • ethers include diethyl ether and tetrahydrofuran.
  • polar aprotic solvents include N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile, and N- methylpyrrolidone .
  • a first aspect of the present invention provides a crystalline Form A of lenvatinib hydrochloride.
  • the crystalline Form A of lenvatinib hydrochloride is characterized by an X-Ray Powder Diffraction (XRPD) pattern having interplanar spacing (d) values at about 16.4, 8.2, and 3.4 (A).
  • the crystalline Form A of lenvatinib hydrochloride is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 14.5, 12.1, 7.2, 5.5, 4.9, and 3.8 (A).
  • the crystalline Form A of lenvatinib hydrochloride is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 5.4, 10.8, and 26.2 ⁇ 0.2°.
  • the crystalline Form A of lenvatinib hydrochloride is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 6.1, 7.3, 12.3, 16.2, 18.3, and 23.4 ⁇ 0.2°.
  • Table 1 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline Form A of lenvatinib hydrochloride.
  • the crystalline Form A of lenvatinib hydrochloride is characterized by an X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
  • the crystalline Form A of lenvatinib hydrochloride is characterized by a Differential Scanning Calorimetry (DSC) thermogram having endothermic peak values at about 77.93°C and 186.18°C.
  • DSC Differential Scanning Calorimetry
  • the crystalline Form A of lenvatinib hydrochloride is characterized by a DSC thermogram as depicted in Figure 2.
  • the crystalline Form A of lenvatinib hydrochloride is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
  • FTIR Fourier-Transform Infrared
  • a second aspect of the present invention provides a crystalline Form A of lenvatinib hydrobromide.
  • the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern having interplanar spacing (d) values at about 17.1, 4.7, 4.6, 4.4, and 3.4 (A).
  • the crystalline Form A of lenvatinib hydrobromide is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.2, 8.6, 6.6, 6.1, 4.0, 3.4, 3.3, and 3.2 (A).
  • the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 5.2, 18.8, 19.2, 20.2, and 26.4 ⁇ 0.2°.
  • the crystalline Form A of lenvatinib hydrobromide is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 6.7, 10.3, 13.5, 14.5, 22.5, 25.9, 27.1, and 28.2 ⁇ 0.2°.
  • Table 2 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline Form A of lenvatinib hydrobromide.
  • the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern substantially as depicted in Figure 4.
  • the crystalline Form A of lenvatinib hydrobromide may be characterized by a DSC thermogram having endothermic peak values at about 73.28°C, 183.20°C, 198.16°C, and 211.15°C.
  • the crystalline Form A of lenvatinib hydrobromide is characterized by a DSC thermogram as depicted in Figure 5.
  • the crystalline Form A of lenvatinib hydrobromide may be characterized by a FTIR spectrum as depicted in Figure 6.
  • a third aspect of the present invention provides a crystalline Form A of lenvatinib tosylate.
  • the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern having interplanar spacing (d) values at about 18.3, 8.5, 7.1, 5.6, and 3.6 (A).
  • the crystalline Form A of lenvatinib tosylate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 5.1, 5.0, 4.5, 4.3, 4.2, 4.1, and 3.4 (A).
  • the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.8, 10.3, 12.4, 15.8, and 24.6 ⁇ 0.2°.
  • the crystalline Form A of lenvatinib tosylate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 17.5, 17.7, 19.9, 20.6, 21.2, 21.9, and 26.5 ⁇ 0.2°.
  • Table 3 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline Form A of lenvatinib tosylate.
  • the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern substantially as depicted in Figure 7.
  • the crystalline Form A of lenvatinib tosylate is characterized by a DSC thermogram having endothermic peak values at about 52.63°C, and 253.29°C.
  • the crystalline Form A of lenvatinib tosylate is characterized by a DSC thermogram as depicted in Figure 8.
  • the crystalline Form A of lenvatinib tosylate is characterized by a FTIR spectrum as depicted in Figure 9.
  • a fourth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib hydrochloride comprising the steps of:
  • Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
  • Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with hydrochloric acid.
  • Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with hydrochloric acid to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
  • the treatment of lenvatinib free base with hydrochloric acid includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a solvent at a temperature of about 20°C to about 35°C for a time period sufficient to complete the reaction.
  • the molar ratio of lenvatinib free base to hydrochloric acid is about 1 :0.5 to about 1:2.
  • the molar ratio of lenvatinib free base to hydrochloric acid is about 1 : 1.
  • the crystalline Form A of lenvatinib hydrochloride can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
  • a fifth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib hydrobromide comprising the steps of:
  • Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
  • Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with hydrobromic acid.
  • Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with hydrobromic acid to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
  • the treatment of lenvatinib free base with hydrobromic acid includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of solvent at a temperature of about 20°C to about 35°C for a time period sufficient to complete the reaction.
  • the molar ratio of lenvatinib free base to hydrobromic acid may be about 1 :0.5 to about 1 :2, which may be preferably 1: 1.
  • the crystalline Form A of lenvatinib hydrobromide can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
  • a sixth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib tosylate comprising the steps of:
  • step b) treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof at a temperature of 40°C to reflux temperature;
  • Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
  • Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with p-toluenesulphonic acid or hydrate thereof to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
  • Step a) of providing a mixture of lenvatinib free base in a solvent includes dissolving or suspending lenvatinib free base in a solvent at a temperature of about 25°C to reflux temperature optionally under stirring.
  • Step b) of treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof includes adding, slurrying, dissolving, stirring, or a combination thereof at a temperature of about 40°C to reflux temperature for a time period sufficient to complete the reaction.
  • the molar ratio of lenvatinib free base to p-toluenesulphonic acid or hydrate thereof may be about 1 :0.5 to about 1 :2, which may be preferably 1: 1.
  • a seventh aspect of the present invention provides the use of crystalline Form A of lenvatinib hydrochloride, crystalline Form A of lenvatinib hydrobromide, or crystalline Form A of lenvatinib tosylate for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
  • crystalline Form A of lenvatinib hydrochloride, crystalline Form A of lenvatinib hydrobromide, or crystalline Form A of lenvatinib tosylate can be converted to lenvatinib free base by contacting with a base.
  • the base may be selected from the group consisting of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals, ammonia, alkyl amines, and hydrazine.
  • hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate.
  • alkyl amines include diethylamine, triethylamine, and methyldiethylamine.
  • Lenvatinib free base thus obtained may be converted to salts, solvates, or polymorphs thereof by any of the methods known in the art.
  • lenvatinib free base obtained may be converted to the mesylate salt.
  • An eighth aspect of the present invention provides a pharmaceutical composition comprising crystalline Form A of lenvatinib hydrochloride, a crystalline Form A of lenvatinib hydrobromide, or a crystalline Form A of lenvatinib tosylate and a pharmaceutically acceptable carrier.
  • Methanolic hydrochloric acid (8% w/w, 0.53 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 25°C to 30°C and stirred for 1 hour.
  • the solid obtained was filtered and then washed with methanol (2 mL). The solid was dried under reduced pressure at 45°C to 50°C for 15 hours to obtain the title compound.
  • p-Toluenesulphonic acid hydrate (0.27 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C to 75°C. The reaction mixture was cooled to 25°C to 30°C and then stirred for 15 hours. The solid obtained was filtered and then washed with ethanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
  • Aqueous ammonia solution (15%) was added to a mixture of lenvatinib hydrochloride (2 g) and deionized water (30 mL) to adjust the pH to 10. The reaction mixture was stirred at 24°C to 26°C for 60 minutes. The solid obtained was filtered, washed with deionized water (2x5 mL), and then dried in air oven at 50°C to 55°C to obtain the title compound.
  • Methanesulphonic acid (0.5 g) was added to a mixture of lenvatinib free base (1 g, obtained from lenvatinib hydrochloride) and isopropyl alcohol (30 mL) at 65 °C. The mixture was stirred at 60°C to 65°C for 5 hours, cooled to 25°C, and then stirred at 25°C to 26°C. The solid was filtered, washed with isopropyl alcohol (2x5 mL), and then dried in vacuum at 50°C to 55°C to obtain the title compound.
  • Aqueous ammonia solution (15%) was added to a mixture of lenvatinib hydrobromide (1.5 g) and deionized water (25 mL) to adjust the pH to 10. The reaction mixture was stirred at 24°C to 26°C for 30 minutes. The solid obtained was filtered, washed with deionized water (2x5 mL), and then dried in air oven at 50°C to 55°C to obtain the title compound.
  • Methanesulphonic acid (0.22 g) was added to a mixture of lenvatinib free base (0.5 g, obtained from lenvatinib hydrobromide) and isopropyl alcohol (15 mL) at 65°C. The mixture was stirred at 60°C to 65°C for 5 hours, cooled to 25°C, and then stirred for 60 minutes. The solid obtained was filtered, washed with isopropyl alcohol (5 mL), and then dried in vacuum at 50°C to 55°C to obtain the title compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a crystalline form of lenvatinib hydrochloride, a crystalline form of lenvatinib hydrobromide, a crystalline form of lenvatinib tosylate, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these crystalline forms of salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.

Description

CRYSTALLINE FORMS OF SALTS OF LENVATINIB
Field of the Invention
The present invention provides a crystalline form of lenvatinib hydrochloride, a crystalline form of lenvatinib hydrobromide, a crystalline form of lenvatinib tosylate, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these crystalline forms of salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
Background of the Invention
Lenvatinib mesylate of Formula I is chemically known as 4-[3-chloro-4-(N'- cyclopropylureido)phenoxy] -7-methoxyquinoline-6-carboxamide methanesulfonate .
Figure imgf000002_0001
Formula I
Lenvatinib mesylate is a kinase inhibitor indicated for the treatment of differentiated thyroid cancer (DTC) as single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine -refractory DTC and for the treatment of renal cell cancer (RCC) in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
U.S. Patent No. 7,253,286 provides a process for the preparation of lenvatinib.
U.S. Patent No. 7,612,208 provides processes for the preparation of crystalline lenvatinib hydrochloride, crystalline lenvatinib hydrobromide, and crystalline lenvatinib tosylate.
There is a need for the development of a salt of lenvatinib and its polymorph having improved solubility, stability, bioavailability, storage and handling stability, and less susceptibility to degradation. Summary of the Invention
The present invention provides a crystalline form of lenvatinib hydrochloride, a crystalline form of lenvatinib hydrobromide, a crystalline form of lenvatinib tosylate, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these crystalline forms of salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
Brief Description of the Figures
Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
Figure 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
Figure 3 depicts a Fourier-Transform Infrared (FTIR) spectrum of crystalline Form A of lenvatinib hydrochloride prepared as per Example 1.
Figure 4 depicts an XRPD pattern of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
Figure 5 depicts a DSC thermogram of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
Figure 6 depicts a FTIR spectrum of crystalline Form A of lenvatinib hydrobromide prepared as per Example 2.
Figure 7 depicts an XRPD pattern of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
Figure 8 depicts a DSC thermogram of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
Figure 9 depicts a FTIR spectrum of crystalline Form A of lenvatinib tosylate prepared as per Example 3.
Detailed Description of the Invention
The term "about," as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value. The term "solvent," includes single solvents or solvent mixtures, such as water, esters, alkanols, halogenated hydrocarbons, ketones, ethers, polar aprotic solvents, or mixtures thereof.
Examples of esters include ethyl acetate, n-propyl acetate, isopropyl acetate, and n- butyl acetate. Examples of alkanols include those primary, secondary, and tertiary alcohols having from one to six carbon atoms. Examples of alkanols include methanol, ethanol, n- propanol, isopropanol, butanol, 2-methoxyethanol, and 2-ethoxyethanol. Examples of halogenated hydrocarbons include dichloromethane, chloroform, and 1,2-dichloroethane. Examples of ketones include acetone and methyl ethyl ketone. Examples of ethers include diethyl ether and tetrahydrofuran. Examples of polar aprotic solvents include N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile, and N- methylpyrrolidone .
A first aspect of the present invention provides a crystalline Form A of lenvatinib hydrochloride.
In one embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by an X-Ray Powder Diffraction (XRPD) pattern having interplanar spacing (d) values at about 16.4, 8.2, and 3.4 (A). The crystalline Form A of lenvatinib hydrochloride is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 14.5, 12.1, 7.2, 5.5, 4.9, and 3.8 (A).
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 5.4, 10.8, and 26.2 ± 0.2°. The crystalline Form A of lenvatinib hydrochloride is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.1, 7.3, 12.3, 16.2, 18.3, and 23.4 ± 0.2°.
Table 1 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline Form A of lenvatinib hydrochloride. Table 1
Figure imgf000005_0001
In one embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by an X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by a Differential Scanning Calorimetry (DSC) thermogram having endothermic peak values at about 77.93°C and 186.18°C.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by a DSC thermogram as depicted in Figure 2.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrochloride is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
A second aspect of the present invention provides a crystalline Form A of lenvatinib hydrobromide.
In one embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern having interplanar spacing (d) values at about 17.1, 4.7, 4.6, 4.4, and 3.4 (A). The crystalline Form A of lenvatinib hydrobromide is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.2, 8.6, 6.6, 6.1, 4.0, 3.4, 3.3, and 3.2 (A).
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 5.2, 18.8, 19.2, 20.2, and 26.4 ± 0.2°. The crystalline Form A of lenvatinib hydrobromide is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.7, 10.3, 13.5, 14.5, 22.5, 25.9, 27.1, and 28.2 ± 0.2°.
Table 2 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline Form A of lenvatinib hydrobromide.
Table 2
Figure imgf000006_0001
In one embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide is characterized by an XRPD pattern substantially as depicted in Figure 4.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide may be characterized by a DSC thermogram having endothermic peak values at about 73.28°C, 183.20°C, 198.16°C, and 211.15°C.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide is characterized by a DSC thermogram as depicted in Figure 5.
In another embodiment of this aspect, the crystalline Form A of lenvatinib hydrobromide may be characterized by a FTIR spectrum as depicted in Figure 6. A third aspect of the present invention provides a crystalline Form A of lenvatinib tosylate.
In one embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern having interplanar spacing (d) values at about 18.3, 8.5, 7.1, 5.6, and 3.6 (A). The crystalline Form A of lenvatinib tosylate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 5.1, 5.0, 4.5, 4.3, 4.2, 4.1, and 3.4 (A).
In another embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.8, 10.3, 12.4, 15.8, and 24.6 ± 0.2°. The crystalline Form A of lenvatinib tosylate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 17.5, 17.7, 19.9, 20.6, 21.2, 21.9, and 26.5 ± 0.2°.
Table 3 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline Form A of lenvatinib tosylate.
Table 3
Figure imgf000007_0001
3.8 23.3 3.7
3.6 24.6 21.8
3.5 25.1 12.1
3.5 25.7 9.1
3.4 26.5 19.0
3.3 26.8 6.4
3.3 27.3 1.8
3.2 27.5 10.4
3.2 28.3 3.3
3.1 28.7 7.9
3.0 29.3 2.0
3.0 29.9 6.4
2.9 30.7 9.1
2.9 31.1 4.8
2.7 33.1 1.4
2.6 34.2 3.8
2.6 34.4 1.1
In one embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by an XRPD pattern substantially as depicted in Figure 7.
In another embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by a DSC thermogram having endothermic peak values at about 52.63°C, and 253.29°C.
In another embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by a DSC thermogram as depicted in Figure 8.
In another embodiment of this aspect, the crystalline Form A of lenvatinib tosylate is characterized by a FTIR spectrum as depicted in Figure 9.
A fourth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib hydrochloride comprising the steps of:
a) treating lenvatinib free base with hydrochloric acid at a temperature of about 20°C to about 35°C; and
b) isolating the crystalline Form A of lenvatinib hydrochloride.
Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with hydrochloric acid. Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with hydrochloric acid to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
The treatment of lenvatinib free base with hydrochloric acid includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a solvent at a temperature of about 20°C to about 35°C for a time period sufficient to complete the reaction.
The molar ratio of lenvatinib free base to hydrochloric acid is about 1 :0.5 to about 1:2. Preferably, the molar ratio of lenvatinib free base to hydrochloric acid is about 1 : 1.
After completion of the reaction, the crystalline Form A of lenvatinib hydrochloride can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
A fifth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib hydrobromide comprising the steps of:
a) treating lenvatinib free base with hydrobromic acid at a temperature of about 20°C to 35°C; and
b) isolating the crystalline Form A of lenvatinib hydrobromide.
Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with hydrobromic acid.
Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with hydrobromic acid to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
The treatment of lenvatinib free base with hydrobromic acid includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of solvent at a temperature of about 20°C to about 35°C for a time period sufficient to complete the reaction. The molar ratio of lenvatinib free base to hydrobromic acid may be about 1 :0.5 to about 1 :2, which may be preferably 1: 1.
After completion of the reaction, the crystalline Form A of lenvatinib hydrobromide can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
A sixth aspect of the present invention provides a process for the preparation of a crystalline Form A of lenvatinib tosylate comprising the steps of:
a) providing a mixture of lenvatinib free base in a solvent,
b) treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof at a temperature of 40°C to reflux temperature; and
c) isolating the crystalline Form A of lenvatinib tosylate.
Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286 and 7,683, 172.
Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to the treatment with p-toluenesulphonic acid or hydrate thereof to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
Step a) of providing a mixture of lenvatinib free base in a solvent includes dissolving or suspending lenvatinib free base in a solvent at a temperature of about 25°C to reflux temperature optionally under stirring.
Step b) of treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof includes adding, slurrying, dissolving, stirring, or a combination thereof at a temperature of about 40°C to reflux temperature for a time period sufficient to complete the reaction.
The molar ratio of lenvatinib free base to p-toluenesulphonic acid or hydrate thereof may be about 1 :0.5 to about 1 :2, which may be preferably 1: 1.
After completion of the reaction, the crystalline Form A of lenvatinib tosylate can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof. A seventh aspect of the present invention provides the use of crystalline Form A of lenvatinib hydrochloride, crystalline Form A of lenvatinib hydrobromide, or crystalline Form A of lenvatinib tosylate for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
In one embodiment of this aspect, crystalline Form A of lenvatinib hydrochloride, crystalline Form A of lenvatinib hydrobromide, or crystalline Form A of lenvatinib tosylate can be converted to lenvatinib free base by contacting with a base. The base may be selected from the group consisting of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals, ammonia, alkyl amines, and hydrazine. Examples of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate. Examples of alkyl amines include diethylamine, triethylamine, and methyldiethylamine.
Lenvatinib free base thus obtained may be converted to salts, solvates, or polymorphs thereof by any of the methods known in the art. Preferably, lenvatinib free base obtained may be converted to the mesylate salt.
An eighth aspect of the present invention provides a pharmaceutical composition comprising crystalline Form A of lenvatinib hydrochloride, a crystalline Form A of lenvatinib hydrobromide, or a crystalline Form A of lenvatinib tosylate and a pharmaceutically acceptable carrier.
While the present invention has been described in terms of its specific aspects, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Methods:
The details of the instrument used are as follows:
DSC: 821e Mettler Toledo®
FTIR: Perkin Elmer® Spectrum One FT-IR Spectrometer
PXRD of samples were determined using a Rigaku® instrument; Model: MiniFlex600; Detector: D/teX Ultra.
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way. EXAMPLES
Example 1 : Preparation of Crystalline Form A of Lenvatinib Hydrochloride
Methanolic hydrochloric acid (8% w/w, 0.53 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 25°C to 30°C and stirred for 1 hour. The solid obtained was filtered and then washed with methanol (2 mL). The solid was dried under reduced pressure at 45°C to 50°C for 15 hours to obtain the title compound.
Yield: 0.3 g
Example 2: Preparation of Crystalline Form A of Lenvatinib Hydrobromide
Hydrobromic acid in acetic acid (48% w/w, 0.28 g) was added to a mixture of lenvatinib free base (0.5 g) and isopropyl alcohol (10 mL) at 25°C to 30°C and stirred for 1 hour. The reaction mixture was heated to 60°C to 65 °C for 15 minutes, then cooled to 25 °C to 30°C and stirred for 24 hours. The solid obtained was filtered and then washed with isopropyl alcohol (2 mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.54 g
Example 3 : Preparation of Crystalline Form A of Lenvatinib Tosylate
p-Toluenesulphonic acid hydrate (0.27 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C to 75°C. The reaction mixture was cooled to 25°C to 30°C and then stirred for 15 hours. The solid obtained was filtered and then washed with ethanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.6 g
Example 4: Preparation of Lenvatinib Free Base
Aqueous ammonia solution (15%) was added to a mixture of lenvatinib hydrochloride (2 g) and deionized water (30 mL) to adjust the pH to 10. The reaction mixture was stirred at 24°C to 26°C for 60 minutes. The solid obtained was filtered, washed with deionized water (2x5 mL), and then dried in air oven at 50°C to 55°C to obtain the title compound.
Yield: 1.78 g Example 5 : Preparation of Lenvatinib Mesylate
Methanesulphonic acid (0.5 g) was added to a mixture of lenvatinib free base (1 g, obtained from lenvatinib hydrochloride) and isopropyl alcohol (30 mL) at 65 °C. The mixture was stirred at 60°C to 65°C for 5 hours, cooled to 25°C, and then stirred at 25°C to 26°C. The solid was filtered, washed with isopropyl alcohol (2x5 mL), and then dried in vacuum at 50°C to 55°C to obtain the title compound.
Yield: 1.1 g
Example 6: Preparation of Lenvatinib Base
Aqueous ammonia solution (15%) was added to a mixture of lenvatinib hydrobromide (1.5 g) and deionized water (25 mL) to adjust the pH to 10. The reaction mixture was stirred at 24°C to 26°C for 30 minutes. The solid obtained was filtered, washed with deionized water (2x5 mL), and then dried in air oven at 50°C to 55°C to obtain the title compound.
Yield: 1.2 g
Example 7: Preparation of Lenvatinib Mesylate
Methanesulphonic acid (0.22 g) was added to a mixture of lenvatinib free base (0.5 g, obtained from lenvatinib hydrobromide) and isopropyl alcohol (15 mL) at 65°C. The mixture was stirred at 60°C to 65°C for 5 hours, cooled to 25°C, and then stirred for 60 minutes. The solid obtained was filtered, washed with isopropyl alcohol (5 mL), and then dried in vacuum at 50°C to 55°C to obtain the title compound.
Yield: 0.6 g

Claims

We claim:
1. A crystalline Form A of lenvatinib hydrochloride.
2. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by an X-Ray Powder Diffraction (XRPD) pattern having interplanar spacing (d) values at about 16.4, 8.2, and 3.4 (A).
3. The crystalline Form A of lenvatinib hydrochloride according to claim 2, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 14.5, 12.1, 7.2, 5.5, 4.9, and 3.8 (A). 4. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 5.
4, 10.8, and 26.2 ± 0.2°.
5. The crystalline Form A of lenvatinib hydrochloride according to claim 4, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.1, 7.3, 12.3, 16.2, 18.3, and 23.4 ± 0.2°.
6. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
7. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by a Differential Scanning Calorimetry (DSC) thermogram having endothermic peak values at about 77.93°C and 186.18°C.
8. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 2.
9. The crystalline Form A of lenvatinib hydrochloride according to claim 1, wherein the crystalline form is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
10. A crystalline Form A of lenvatinib hydrobromide.
11. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 17.1, 4.7, 4.6, 4.4, and 3.4 (A).
12. The crystalline Form A of lenvatinib hydrobromide according to claim 11, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.2, 8.6, 6.6, 6.1, 4.0, 3.4, 3.3, and 3.2 (A).
13. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 5.2, 18.8, 19.2, 20.2, and 26.4 ± 0.2°.
14. The crystalline Form A of lenvatinib hydrobromide according to claim 13, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.7, 10.3, 13.5, 14.5, 22.5, 25.9, 27.1, and 28.2 ± 0.2°.
15. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 4.
16. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by a DSC thermogram having endothermic peak values at about 73.28°C, 183.20°C, 198.16°C, and 211.15°C.
17. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 5.
18. The crystalline Form A of lenvatinib hydrobromide according to claim 10, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 6.
19. A crystalline Form A of lenvatinib tosylate.
20. The crystalline Form A of lenvatinib tosylate according to claim 19, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 18.3, 8.5, 7.1, 5.6, and 3.6 (A).
21. The crystalline Form A of lenvatinib tosylate according to claim 20, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 5.1, 5.0, 4.5, 4.3, 4.2, 4.1, and 3.4 (A).
22. The crystalline Form A of lenvatinib tosylate according to claim 19, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.8, 10.3, 12.4, 15.8, and 24.6 ± 0.2°.
23. The crystalline Form A of lenvatinib tosylate according to claim 22, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 17.5, 17.7, 19.9, 20.6, 21.2, 21.9, and 26.5 ± 0.2°.
24. The crystalline Form A of lenvatinib tosylate according to claim 19, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 7.
25. The crystalline Form A of lenvatinib tosylate according to claim 19, wherein the crystalline form is characterized by a DSC thermogram having endothermic peak values at about 52.63°C, and 253.29°C.
26. The crystalline Form A of lenvatinib tosylate according to claim 19, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 8.
27. The crystalline Form A of lenvatinib tosylate, according to claim 19, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 9.
28. A process for the preparation of a crystalline Form A of lenvatinib hydrochloride comprising the steps of:
a) treating lenvatinib free base with hydrochloric acid at a temperature of about
20°C to about 35°C; and
b) isolating the crystalline Form A of lenvatinib hydrochloride.
29. The process according to claim 28, wherein the treatment of lenvatinib free base with hydrochloric acid comprises adding, slurrying, dissolving, stirring, or a combination thereof.
30. The process according to claim 28, wherein in the step a) the molar ratio of lenvatinib free base to hydrochloric acid is about 1 :0.5 to about 1:2.
31. The process according to claim 28, wherein the crystalline Form A of lenvatinib hydrochloride is isolated by a method involving cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
32. A process for the preparation of a crystalline Form A of lenvatinib hydrobromide comprising the steps of:
a) treating lenvatinib free base with hydrobromic acid at a temperature of about
20°C to 35°C; and b) isolating the crystalline Form A of lenvatinib hydrobromide.
33. The process according to claim 32, wherein the treatment of lenvatinib free base with hydrobromic acid comprises adding, slurrying, dissolving, stirring, or a combination thereof.
34. The process according to claim 32, wherein in the step a) the molar ratio of lenvatinib free base to hydrobromic acid is about 1 : 0.5 to about 1 :2.
35. The process according to claim 32, wherein the crystalline Form A of lenvatinib hydrobromide is isolated by a method involving cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
36. A process for the preparation of a crystalline Form A of lenvatinib tosylate comprising the steps of:
a) providing a mixture of lenvatinib free base in a solvent;
b) treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof at a temperature of 40°C to reflux temperature; and
c) isolating the crystalline Form A of lenvatinib tosylate.
37. The process according to claim 36, wherein in the step a) of providing a mixture of lenvatinib free base in a solvent comprises dissolving or suspending lenvatinib free base in a solvent at a temperature of about 25°C to reflux temperature optionally under stirring.
38. The process according to claim 36, wherein in the step b) of treating the mixture obtained in step a) with p-toluenesulphonic acid or hydrate thereof comprises adding, slurrying, dissolving, stirring, or a combination thereof at a temperature of about 40°C to reflux temperature for a time period sufficient to complete the reaction.
39. The process according to claim 36, wherein the molar ratio of lenvatinib free base to p-toluenesulphonic acid or hydrate thereof is about 1 : 0.5 to about 1 :2.
40. The process according to claim 36, wherein the crystalline Form A of lenvatinib tosylate is isolated by a method involving cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying or combinations thereof.
41. Use of a crystalline Form A of lenvatinib hydrochloride, a crystalline Form A of lenvatinib hydrobromide, or a crystalline Form A of lenvatinib tosylate for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
42. A pharmaceutical composition comprising a crystalline Form A of lenvatinib hydrochloride, a crystalline Form A of lenvatinib hydrobromide, or a crystalline Form A of lenvatinib tosylate and a pharmaceutically acceptable carrier.
PCT/IB2017/053776 2016-06-23 2017-06-23 Crystalline forms of salts of lenvatinib WO2017221214A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611021562 2016-06-23
IN201611021562 2016-06-23

Publications (1)

Publication Number Publication Date
WO2017221214A1 true WO2017221214A1 (en) 2017-12-28

Family

ID=60784097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053776 WO2017221214A1 (en) 2016-06-23 2017-06-23 Crystalline forms of salts of lenvatinib

Country Status (1)

Country Link
WO (1) WO2017221214A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229103A (en) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 A kind of pleasure is cut down for the preparation method of Buddhist nun's Mesylate Form B
EP3632436A1 (en) * 2018-10-04 2020-04-08 Synthon B.V. Pharmaceutical composition comprising lenvatinib salts
WO2020070144A1 (en) * 2018-10-04 2020-04-09 Synthon B.V. Crystalline forms and processes of lenvatinib besylate
CN111051285A (en) * 2017-08-21 2020-04-21 迪氏曼卡博金艾美斯有限公司 Octenidine-based compounds
RU2801812C2 (en) * 2018-10-04 2023-08-16 Синтон Б.В. Crystalline forms and methods for obtaining lenvatinib besylate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037849A1 (en) * 2003-11-11 2007-02-15 Toshihiko Naito Urea derivative and process for producing the same
US20070078159A1 (en) * 2003-12-25 2007-04-05 Tomohiro Matsushima A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amin ophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
US20100324087A1 (en) * 2008-01-29 2010-12-23 Eisai R&D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037849A1 (en) * 2003-11-11 2007-02-15 Toshihiko Naito Urea derivative and process for producing the same
US20070078159A1 (en) * 2003-12-25 2007-04-05 Tomohiro Matsushima A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amin ophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
US20100324087A1 (en) * 2008-01-29 2010-12-23 Eisai R&D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OKAMOTO, K ET AL.: "Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. Issue 1, pages 89 - 94, XP055445709 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111051285A (en) * 2017-08-21 2020-04-21 迪氏曼卡博金艾美斯有限公司 Octenidine-based compounds
EP3632436A1 (en) * 2018-10-04 2020-04-08 Synthon B.V. Pharmaceutical composition comprising lenvatinib salts
WO2020070147A1 (en) * 2018-10-04 2020-04-09 Synthon B.V. Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2020070144A1 (en) * 2018-10-04 2020-04-09 Synthon B.V. Crystalline forms and processes of lenvatinib besylate
CN113226316A (en) * 2018-10-04 2021-08-06 斯索恩有限公司 Crystalline forms and processes of lenvatinib besylate
RU2801812C2 (en) * 2018-10-04 2023-08-16 Синтон Б.В. Crystalline forms and methods for obtaining lenvatinib besylate
US12102630B2 (en) 2018-10-04 2024-10-01 Synthon B.V. Crystalline forms and processes of lenvatinib besylate
CN110229103A (en) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 A kind of pleasure is cut down for the preparation method of Buddhist nun's Mesylate Form B

Similar Documents

Publication Publication Date Title
WO2017221214A1 (en) Crystalline forms of salts of lenvatinib
US9056112B2 (en) Process for preparation of pure linagliptin
WO2017016960A1 (en) Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
CA2594690C (en) Salts of aripiprazole
JP2014521726A5 (en)
US20110237802A1 (en) Lenalidomide solvates and processes
EP2760853A1 (en) Novel salts of alogliptin
EP2870155A1 (en) Ticagrelor adducts with divalent metal salts
WO2009109651A1 (en) SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
SK7066Y1 (en) Crystalline dihydrate bilastine
WO2003101991A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
US20190194154A1 (en) Polymorphic Forms Of Vortioxetine Hydrobromide Tert-Butanolate
US10941116B2 (en) Crystalline forms of mesaconine and preparation methods therefor
CN117736203A (en) Method for synthesizing valphenazine
WO2014009970A2 (en) Linagliptin solid dispersion
EP2243780A2 (en) Process for the purification of paliperidone
WO2017221215A1 (en) Salts of lenvatinib
WO2011036648A1 (en) Polymorphs of sorafenib acid addition salts
WO2015092624A1 (en) Nilotinib mono-oxalate and its crystalline form
WO2017081014A1 (en) Process for the preparation of eltrombopag olamine
EP2970320B1 (en) Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
US20080146805A1 (en) Process for the Production of Levorphanol and Related Compounds
EP2139899A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
WO2014118737A1 (en) Erlotinib salts
WO2015114479A1 (en) Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17814875

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17814875

Country of ref document: EP

Kind code of ref document: A1